Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EMEA gives guidance for biosimilar IFN

EMEA published a draft guideline detailing the requirements for applications seeking approval of biosimilars containing recombinant interferon (IFN) alpha. In

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE